Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cancers|January 9, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Yanina Jansen, Julia Katharina Schwarze, et al.
Revista Da Sociedade Brasileira De Medicina Tropical|February 23, 2023
Subclinical signs of podocyte injury associated with Circulating Anodic Antigen (CAA) in Schistosoma mansoni-infected patients in BrazilMariana Silva Sousa, Gdayllon Cavalcante Meneses, Govert Jan van Dam, et al.
The Journal of Pathology. Clinical Research|June 20, 2018
Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastasesRaymond Barnhill, Peter Vermeulen, Sofie Daelemans, et al.
The Journal of Pathology. Clinical Research|April 19, 2020
Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic valueRaymond Barnhill, Pieter-Jan van Dam, Peter Vermeulen, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
The Prostate|February 13, 2018
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancerBram De Laere, Steffi Oeyen, Peter Van Oyen, et al.
Genome Medicine|November 22, 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisMarkus Mayrhofer, Bram De Laere, Tom Whitington, et al.
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
NPJ Precision Oncology|March 11, 2025
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancerPieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, et al.
Pageof 5